Changes in Hong Kong stocks | Jingfang Pharmaceutical-B (02595) rose nearly 5% in early trading, GFH276 received clinical licenses to conduct research at home and abroad

The Zhitong Finance App learned that Jinfang Pharmaceutical-B (02595) rose nearly 5% in early trading. As of press release, it rose 3.84% to HK$19.48, with a turnover of HK$156.191,000.

According to the news, Jinfang Pharmaceutical announced that since the third quarter of this year, a number of innovative combination therapies for oral administration of the pan-RAS inhibitor GFH276 have obtained clinical trial permits issued by the domestic CDE or completed the Australian TGA clinical trial registration. Relevant studies cover first-line and post-line treatment of multiple RAS mutation tumors. Some trials have enrolled patients at multiple dose levels.

According to a research report released by China Merchants Securities, GFH276 is the first positive human data. The PDAC 41% ORR and 14.8% grade 3 TRAE are core highlights. The combination of early efficacy and safety shows the potential to be superior to RMC-6236's data over the same period, and has the potential BIC competitiveness of global pan-ras inhibitors.